JWH-359: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{DISPLAYTITLE:JWH-359}} | |||
== | == Overview == | ||
JWH-359 is | '''JWH-359''' is a synthetic cannabinoid that acts as a potent agonist of the [[cannabinoid receptor]]s. It is part of the [[JWH series]] of compounds, which were developed by Dr. [[John W. Huffman]] and his team in the 1990s. JWH-359 is primarily known for its high affinity for the [[CB2 receptor]], which is predominantly found in the [[immune system]]. | ||
== | == Chemical Structure == | ||
[[File:JWH-359_Structure.svg|thumb|right|Chemical structure of JWH-359]] | |||
JWH-359 is a member of the naphthoylindole family of synthetic cannabinoids. Its chemical structure is characterized by a naphthoyl group attached to an indole core. The specific configuration of JWH-359 allows it to interact selectively with cannabinoid receptors, particularly the CB2 receptor. | |||
== | == Pharmacology == | ||
JWH-359 exhibits a high selectivity for the [[CB2 receptor]] over the [[CB1 receptor]], which is primarily located in the [[central nervous system]]. This selectivity makes it of interest for research into [[anti-inflammatory]] and [[immunomodulatory]] effects, as CB2 receptor activation is associated with modulation of immune responses. | |||
== | === Mechanism of Action === | ||
JWH-359 acts as a full agonist at the CB2 receptor, meaning it binds to the receptor and activates it to produce a biological response. This activation can lead to various effects, including the modulation of [[cytokine]] release and the inhibition of [[inflammatory]] pathways. | |||
== | == Potential Applications == | ||
Due to its selectivity for the CB2 receptor, JWH-359 has been studied for potential therapeutic applications in conditions such as [[autoimmune diseases]], [[chronic pain]], and [[neurodegenerative disorders]]. However, its use is limited to research settings, and it is not approved for medical use. | |||
== Legal Status == | |||
JWH-359, like many synthetic cannabinoids, is subject to legal restrictions in many countries. It is often classified as a controlled substance due to its potential for abuse and lack of approved medical use. | |||
== Safety and Toxicity == | |||
The safety profile of JWH-359 is not well-established, as it is primarily used in research. Synthetic cannabinoids, in general, can have unpredictable effects and may pose health risks, including [[cardiovascular]] and [[neurological]] effects. | |||
== Related Pages == | |||
* [[Cannabinoid receptor]] | * [[Cannabinoid receptor]] | ||
* [[ | * [[Synthetic cannabinoid]] | ||
* [[CB2 receptor]] | |||
* [[JWH series]] | |||
[[Category:Synthetic cannabinoids]] | [[Category:Synthetic cannabinoids]] | ||
[[Category: | [[Category:Research chemicals]] | ||
Latest revision as of 03:40, 13 February 2025
Overview[edit]
JWH-359 is a synthetic cannabinoid that acts as a potent agonist of the cannabinoid receptors. It is part of the JWH series of compounds, which were developed by Dr. John W. Huffman and his team in the 1990s. JWH-359 is primarily known for its high affinity for the CB2 receptor, which is predominantly found in the immune system.
Chemical Structure[edit]
JWH-359 is a member of the naphthoylindole family of synthetic cannabinoids. Its chemical structure is characterized by a naphthoyl group attached to an indole core. The specific configuration of JWH-359 allows it to interact selectively with cannabinoid receptors, particularly the CB2 receptor.
Pharmacology[edit]
JWH-359 exhibits a high selectivity for the CB2 receptor over the CB1 receptor, which is primarily located in the central nervous system. This selectivity makes it of interest for research into anti-inflammatory and immunomodulatory effects, as CB2 receptor activation is associated with modulation of immune responses.
Mechanism of Action[edit]
JWH-359 acts as a full agonist at the CB2 receptor, meaning it binds to the receptor and activates it to produce a biological response. This activation can lead to various effects, including the modulation of cytokine release and the inhibition of inflammatory pathways.
Potential Applications[edit]
Due to its selectivity for the CB2 receptor, JWH-359 has been studied for potential therapeutic applications in conditions such as autoimmune diseases, chronic pain, and neurodegenerative disorders. However, its use is limited to research settings, and it is not approved for medical use.
Legal Status[edit]
JWH-359, like many synthetic cannabinoids, is subject to legal restrictions in many countries. It is often classified as a controlled substance due to its potential for abuse and lack of approved medical use.
Safety and Toxicity[edit]
The safety profile of JWH-359 is not well-established, as it is primarily used in research. Synthetic cannabinoids, in general, can have unpredictable effects and may pose health risks, including cardiovascular and neurological effects.
